Fingerprint spectrum of spleen-strengthening pill and determination method of multi-component content

Through optimized pretreatment and high-performance liquid chromatography methods, the content determination method of 5 ingredients in Jianpi Pills and the fingerprint map of 8 index components was established, which solved the problem that could not be comprehensively determined in the existing technology and realized Jianpi Pills Comprehensive evaluation of quality and stability control.

CN118937519APending Publication Date: 2024-11-12HEHUANG PHARMA SHANGHAI

Patent Information

Application Number
CN202411051225.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art can only measure the hesperidin content in Jianpi Pills, but cannot comprehensively determine other components. The lack of methods for multi-component simultaneous determination of Chinese medicines, which affects the quality control and efficacy evaluation of traditional Chinese medicine.

Method used

The content determination method for 5 components in Jianpi Pills (hesperidin, ferulic acid, naringin, neohesperidin, and Atractylodesophaginal lactone I) was established based on the optimization of pretreatment and high-performance liquid chromatography. The fingerprint map of Jianpi Pills is determined by 8 index components, providing reference for quality control and evaluation.

Benefits of technology

Quantitative analysis of 5 ingredients in Jianpi Pills and fingerprint maps of 8 indicator ingredients were achieved, ensuring comprehensive evaluation and stability of drug quality and improving drug safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004974988150000031
    Figure BDA0004974988150000031
  • Figure BDA0004974988150000041
    Figure BDA0004974988150000041
  • Figure BDA0004974988150000061
    Figure BDA0004974988150000061
Patent Text Reader

Abstract

The invention provides a method for measuring contents of various components in spleen-strengthening pills. The invention also provides a detection method of the spleen-strengthening pill fingerprint spectrum. The invention further provides application of the spleen-strengthening pill fingerprint detection method in quality detection of components in spleen-strengthening pills. The invention further provides a quality detection method of the spleen-strengthening pill. The invention further provides a screening method of the fingerprint spectrum of the multiple medicinal materials in the spleen-strengthening pill. According to the spleen-strengthening pill fingerprint spectrum and the multi-component content determination method provided by the invention, five components in the spleen-strengthening pill can be quantitatively analyzed, a high performance liquid fingerprint spectrum of the spleen-strengthening pill is also established, and eight index components reflecting six medicinal materials in the spleen-strengthening pill are provided, so that a scientific basis is provided for controlling the quality of the pill.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of Chinese medicine component detection, and relates to a Jianpi Pill fingerprint spectrum and a method for determining the content of multiple components, and specifically relates to a method for determining the contents of five components in the Jianpi Pill: hesperidin, ferulic acid, naringin, neohesperidin, and atractylodes lactone I, and a fingerprint spectrum determined based on eight indicator components. Background Art

[0002] Jianpi Pills originated from the ancient classic prescription "Yi Fang Ji Jie". It is a compound preparation composed of six Chinese medicines: Codonopsis pilosula, stir-fried Atractylodes macrocephala, stir-fried malt, stir-fried hawthorn, immature bitter orange (fried), and dried orange peel. It is a commonly used prescription for digestion and stagnation. Among them, Codonopsis pilosula and Atractylodes macrocephala can invigorate Qi and strengthen the spleen to replenish spleen deficiency, and they are the main medicines; hawthorn and malt can digest food and eliminate stagnation to eliminate food accumulation, and they are the assistant medicines; immature bitter orange and dried orange peel are used to regulate Qi and harmonize the stomach. Immature bitter orange and dried orange peel play the role of breaking Qi and eliminating accumulation, regulating Qi and strengthening the spleen, and resolving phlegm and dispersing lumps. It is clinically used to treat poor appetite, loose stools, abdominal distension, and weak spleen and stomach.

[0003] This preparation is included in the 2020 edition of the Chinese Pharmacopoeia, and its quality control only measured the hesperidin content. Related literature also studied the quality methods of ingredients such as codonopsis pilosula, atractylodes lactones, and flavonoids. However, the quality and efficacy of traditional Chinese medicine advocate integrity, so the simultaneous determination of multiple components can more comprehensively reflect its quality. Summary of the invention

[0004] In view of the shortcomings of the prior art described above, the purpose of the present invention is to provide a fingerprint spectrum of Jianpi Pills and a method for determining the content of multiple components. By using pretreatment under optimized conditions and high performance liquid chromatography, a method for determining the contents of five components in Jianpi Pills: hesperidin, ferulic acid, naringin, neohesperidin, and atractylodes lactone I, and a fingerprint spectrum determined based on eight index components: hesperidin, ferulic acid, naringin, neohesperidin, atractylodes lactone I, naringin, galangin, and nobiletin are established, so as to provide a reference for controlling and evaluating the quality of Jianpi Pills.

[0005] To achieve the above-mentioned and other related purposes, the present invention provides a method for determining the contents of multiple components in Jianpi Pills in a first aspect, comprising the following steps:

[0006] 1) Preparation of the test solution: dissolve the Jianpi Pill sample in a solvent, extract with ultrasound, cool, filter, and take the filtrate to obtain the test solution;

[0007] 2) Preparation of the first reference solution and / or the second reference solution, comprising any one or more of the following steps:

[0008] 21) Add the reference substances of ferulic acid, naringin, neohesperidin and atractylodes lactone I into the solvent, dissolve them and then make up to volume to obtain the first reference substance solution;

[0009] 22) Add the solvent to the hesperidin reference substance, dissolve it and then make up the volume to obtain the second reference substance solution;

[0010] 3) Determination: The test solution of step 1), the first reference solution of step 21) and / or the second reference solution of step 22) are respectively determined by high performance liquid chromatography (HPLC), and the contents of the five components in the test solution are calculated by external standard method.

[0011] Preferably, in step 1), the Jianpi Pills sample is a powder sample obtained by crushing the Jianpi Pills.

[0012] Preferably, in step 1), the Jianpi Pills sample is accurately weighed before adding the solvent.

[0013] Preferably, in step 1) or 2), the solvent is methanol.

[0014] Preferably, in step 1), the ratio of the weight (g) of the Jianpi Pills sample added to the volume (mL) of the solvent added is 0.01-1.5:25, specifically 0.01-0.04:25, 0.04-1.1:25, 1.1-1.5:25, preferably 0.04-1.1:25.

[0015] More preferably, when detecting the four ingredients in Jianpi Pills: ferulic acid, naringin, neohesperidin, and Atractylodes lactone I, the ratio of the weight (g) of the Jianpi Pills sample added to the volume (mL) of the solvent added is 0.9-1.1:25, preferably 1:25; when detecting hesperidin in Jianpi Pills, the ratio of the weight (g) of the Jianpi Pills sample added to the volume (mL) of the solvent added is 0.04-0.06:25, preferably 0.05:25.

[0016] Since the content of hesperidin in Jianpi Pills samples is relatively high, it will affect the quantification of other components. Therefore, content determination methods for the simultaneous quantification of the four components in Jianpi Pills and the separate quantification of hesperidin were established.

[0017] Preferably, in step 1), the ultrasonic extraction time is 40-80 min, specifically 40-60 min, 60-40 min, 50-70 min, preferably 60 min.

[0018] Preferably, in step 1), the power of the ultrasonic extraction is 200-300 W, preferably 250 W; the frequency of the ultrasonic extraction is 30-50 kHz, preferably 40 kHz.

[0019] Preferably, in step 1), the cooling is cooling to room temperature. The room temperature is 20-30°C.

[0020] Preferably, in step 1), the filtration is membrane filtration.

[0021] More preferably, the filter membrane is a 0.45 μm filter membrane.

[0022] Preferably, in step 2), the first reference substance solution and / or the second reference substance solution are prepared by first adding a solvent to prepare a reference substance stock solution and then adding a solvent to dilute step by step.

[0023] Preferably, in step 2), the CAS number of ferulic acid is 1135-24-6, the CAS number of naringin is 10236-47-2, the CAS number of neohesperidin is 13241-33-3, the CAS number of atractylodes lactone I is 73069-13-3, and the CAS number of hesperidin is 520-26-3.

[0024] Preferably, in step 21), the content range of ferulic acid in the first reference solution is 1.50-96.06 μg / mL, preferably 96.06 μg / mL; the content range of naringin is 1.87-119.99 μg / mL, preferably 119.99 μg / mL; the content range of neohesperidin is 1.88-120.11 μg / mL, preferably 120.11 μg / mL; the content range of atractylodes lactone I is 0.75-48.11 μg / mL, preferably 48.11 μg / mL.

[0025] Preferably, in step 22), the content of hesperidin in the second reference solution is in the range of 6.20-397 μg / mL, preferably 397 μg / mL.

[0026] Preferably, in step 3), the chromatographic column in the high performance liquid chromatography is C 18 More preferably, the chromatographic column in the high performance liquid chromatography is Agilent ZORBAX SB-C 18 Chromatographic column: Chromatographic column (250 mm × 4.6 mm, 5 μm).

[0027] Preferably, in step 3), the detector in the HPLC method is a photodiode array detector (DAD).

[0028] Preferably, in step 3), in the high performance liquid chromatography, the column temperature is 25-35°C, such as 25-30°C, 30-35°C, 28-32°C, preferably 30°C.

[0029] Preferably, in step 3), the injection volume in the HPLC method is 5-20 μL. More preferably, the injection volume in the HPLC method is 10 μL.

[0030] Preferably, in step 3), the flow rate in the high performance liquid chromatography is 0.5-2 mL / min, such as 0.5-1 mL / min, 1-2 mL / min, 0.8-1.2 mL / min, and preferably 1 mL / min.

[0031] Preferably, in step 3), the detection wavelength in the high performance liquid chromatography is selected from one or more combinations of 274-276 nm, 299-301 nm, 319-321 nm, preferably one or more combinations of 275 nm, 300 nm, 320 nm.

[0032] More preferably, when detecting four ingredients in Jianpi Pills: ferulic acid, naringin, neohesperidin, and Atractylodes lactone I, the detection wavelengths are 275 nm, 300 nm, and 320 nm.

[0033] Further preferably, the detection wavelength changes with the time of the gradient elution program. The specific changes are shown in Table 1, which are: 0-12 min, the detection wavelength is 275 nm; 12-21 min, the detection wavelength is 300 nm; 21-34 min, the detection wavelength is 275 nm; 34-35 min, the detection wavelength is 320 nm; 35-37 min, the detection wavelength is 275 nm; 37-48 min, the detection wavelength is 300 nm; 48-60 min, the detection wavelength is 275 nm.

[0034] Table 1

[0035]

[0036] More preferably, when detecting hesperidin in Jianpi Pills, the detection wavelength is 275 nm and 300 nm.

[0037] Further preferably, the detection wavelength changes with the time of the gradient elution program. The specific changes are shown in Table 2, which are: 0-12 min, the detection wavelength is 275 nm; 12-21 min, the detection wavelength is 300 nm; 21-37 min, the detection wavelength is 275 nm; 37-48 min, the detection wavelength is 300 nm; 48-60 min, the detection wavelength is 275 nm.

[0038] Table 2

[0039]

[0040] The above-mentioned detection wavelength conversion detection technology is based on the full-band scanning of the sample by a diode array detector (DAD). By selecting a specific detection wavelength to analyze the Jianpi Pills, a larger number of chromatographic peaks in the chromatogram can be separated, while reducing the interference between the chromatographic peaks.

[0041] Preferably, in step 3), in the high performance liquid chromatography, the mobile phase is acetonitrile-formic acid aqueous solution.

[0042] More preferably, in the high performance liquid chromatography, the mobile phase is acetonitrile-0.08-0.12% formic acid aqueous solution; in acetonitrile-0.08-0.12% formic acid aqueous solution, phase A is acetonitrile and phase B is 0.08-0.12% formic acid aqueous solution.

[0043] Further preferably, in the high performance liquid chromatography, the mobile phase is acetonitrile-0.1% formic acid aqueous solution; in the acetonitrile-0.1% formic acid aqueous solution, phase A is acetonitrile and phase B is 0.1% formic acid aqueous solution.

[0044] The 0.08-0.12% formic acid aqueous solution is a formic acid aqueous solution with a volume percentage of 0.08-0.12%. The 0.1% formic acid aqueous solution is a formic acid aqueous solution with a volume percentage of 0.1%.

[0045] Preferably, in step 3), the high performance liquid chromatography method uses gradient elution and the analysis time is 60 min.

[0046] More preferably, the specific procedure of the gradient elution is:

[0047] 0-6min, the volume ratio of phase A:phase B was 4-6:94-96-21-23:77-79;

[0048] 6-17min, the volume ratio of phase A:phase B is 21-23:77-79-21-23:77-79;

[0049] 17-19min, the volume ratio of phase A:phase B is 21-23:77-79-30-32:68-70;

[0050] 19-32min, the volume ratio of phase A:phase B is 30-32:68-70-42-44:56-58;

[0051] 32-36min, the volume ratio of phase A:phase B is 42-44:56-58-48-50:50-52;

[0052] 36-42min, the volume ratio of phase A:phase B is 48-50:50-52-62-64:36-38;

[0053] 42-44min, the volume ratio of phase A:phase B is 62-64:36-38-62-64:36-38;

[0054] 44-55min, the volume ratio of phase A:phase B is 62-64:36-38-94-96:4-6;

[0055] 55-60min, the volume ratio of phase A:phase B is 94-96:4-6-4-6:94-96.

[0056] Further preferably, the specific procedure of the gradient elution is:

[0057] 0-6min, the volume ratio of phase A:phase B was 5:95-22:78;

[0058] 6-17min, the volume ratio of phase A:phase B is 22:78-22:78;

[0059] 17-19 min, the volume ratio of phase A:phase B was 22:78-31:69;

[0060] 19-32min, the volume ratio of phase A:phase B was 31:69-43:57;

[0061] 32-36min, the volume ratio of phase A:phase B was 43:57-49:51;

[0062] 36-42min, the volume ratio of phase A:phase B was 49:51-63:37;

[0063] 42-44min, the volume ratio of phase A:phase B was 63:37-63:37;

[0064] 44-55min, the volume ratio of phase A:phase B was 63:37-95:5;

[0065] 55-60min, the volume ratio of phase A:phase B is 95:5-5:95.

[0066] Preferably, in step 3), the external standard method refers to: respectively taking a series of different volumes of the first reference solution in step 21) and the second reference solution in step 22), respectively preparing a series of solutions with different concentrations, and adopting high performance liquid chromatography injection analysis to obtain the linear relationship between the concentration and peak area of ​​the five components in the reference solution, and drawing the corresponding standard working curve with the chromatographic peak area of ​​each component corresponding to its corresponding concentration, and calculating the regression equation of each standard working curve. Then, the test solution is detected by high performance liquid chromatography, and the chromatographic peak areas of the five components in the test solution are respectively substituted into the regression equation of each standard working curve, and the content of the corresponding component can be calculated.

[0067] More preferably, in the standard working curve, the peak area of ​​each component is used as the ordinate, and the concentration of each component in the reference solution is used as the abscissa.

[0068] The second aspect of the present invention provides a method for detecting the fingerprint of Jianpi Pills, comprising the following steps:

[0069] A) Preparation of test solution: the same as step 1) of the method for determining the content of multiple components in Jianpi Pills;

[0070] B) Preparation of the third reference solution: adding a solvent to the reference substances of ferulic acid, naringin, neohesperidin, atractylodes lactone I, hesperidin, naringin, fennel glycosides, and nobiletin, dissolving them and then fixing the volume to prepare the third reference solution;

[0071] C) Determination: adopt high performance liquid chromatography (HPLC) under the same chromatographic conditions as step 3) of the method for determining the contents of multiple components in Jianpi Pills, respectively determine the test solution of step A) and the third reference solution of step B), obtain the fingerprint of the test solution and the fingerprint of the third reference solution, compare the fingerprint of the test solution with the fingerprint of the third reference solution, attribute and locate the index components in the fingerprint of the test solution, thereby obtaining the fingerprint of Jianpi Pills.

[0072] Preferably, in step B), the third reference substance solution is prepared by first adding a solvent to prepare a reference substance stock solution, and then adding a solvent to dilute step by step.

[0073] Preferably, in step B), the solvent is methanol.

[0074] Preferably, in step B), the CAS number of the naringin is 14259-46-2; the CAS number of the citronelloside is 14259-47-3; and the CAS number of the nobiletin is 478-01-3.

[0075] Preferably, in step C), the fingerprint of the test solution is compared with the fingerprint of the third reference solution, and the corresponding characteristic peaks in the fingerprint of the test solution are identified by relative retention time based on the known characteristic peaks in the fingerprint of the third reference solution, thereby attributing and locating the indicator components in the fingerprint of the test solution.

[0076] The third aspect of the present invention provides a method for detecting the fingerprint of Jianpi Pills and its use in quality detection of ingredients in Jianpi Pills.

[0077] The fourth aspect of the present invention provides a quality detection method for Jianpi Pills, comprising obtaining a Jianpi Pills fingerprint spectrum by using the aforementioned Jianpi Pills fingerprint spectrum detection method, and comparing the obtained Jianpi Pills fingerprint spectrum with a control fingerprint spectrum of Jianpi Pills obtained under the same fingerprint spectrum detection conditions for similarity.

[0078] Preferably, when the present invention compares the similarity of the measured Jianpi Pills fingerprint spectrum with the control fingerprint spectrum of Jianpi Pills, the software of "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" 2012 version issued by the State Pharmacopoeia Committee is used for comparison. More preferably, the similarity of the Jianpi Pills fingerprint spectrum measured by the present invention with the control fingerprint spectrum of Jianpi Pills is greater than 0.99.

[0079] More preferably, when the Jianpi Pills fingerprint spectrum is matched with the Jianpi Pills control fingerprint spectrum for fingerprint common peaks, the time window width is 0.20, multi-point correction matching is adopted, and the fingerprint spectrum and the control fingerprint spectrum are generated by the average method.

[0080] Preferably, the control fingerprint of Jianpi Pills is obtained under the same conditions as the detection method of the aforementioned Jianpi Pills fingerprint. The control fingerprint of Jianpi Pills is shown in Table 3, including 25 common fingerprint peaks, with peak 12 as the reference peak (S peak, relative retention time is 1.0000), and the relative retention times of the other 24 peaks are peak 1 (0.2411±0.0010), peak 2 (0.2884±0.000 8), peak 3 (0.4558±0.0003), peak 4 (0.4957±0.0005), peak 5 (0.6639±0.0019), peak 6 (0.7026±0.0015), peak 7 (0.7127±0.0015), peak 8 (0.7514±0.0011), peak 9 (0.7675±0.0007), peak 10 (0.92 65±0.0015), peak 11 (0.9722±0.0005), peak 13 (1.0442±0.0007), peak 14 (1.0847±0.0015), peak 15 (1.1980±0.0025), peak 16 (1.2170±0.0019), peak 17 (1.3964±0.0018), peak 18 (1.4168±0. 0023), peak 19 (1.4664±0.0023), peak 20 (1.4851±0.0025), peak 21 (1.4997±0.0026), peak 22 (1.5250±0.0026), peak 23 (1.5353±0.0006), peak 24 (1.5422±0.0012), and peak 25 (1.5973±0.0015).

[0081] Table 3 Relative retention time of common peaks in fingerprints (n=20)

[0082]

[0083]

[0084] The specific data of the control fingerprint of the Jianpi Pills can be found inFigure 4 .

[0085] More preferably, the control fingerprint of the Jianpi Pills is compared with the fingerprint of the third reference solution, such as Figure 6 , 8 As shown in , 9, it is determined that peak No. 9 is the fingerprint peak of ferulic acid; peak No. 10 is the fingerprint peak of naringin; peak No. 11 is the fingerprint peak of naringin; peak No. 12 is the fingerprint peak of hesperidin; peak No. 13 is the fingerprint peak of neohesperidin; peak No. 15 is the fingerprint peak of valerianthin; peak No. 20 is the fingerprint peak of nobiletin; peak No. 25 is the fingerprint peak of atractylodes lactone I.

[0086] The fifth aspect of the present invention provides a method for screening fingerprints of multiple medicinal materials in Jianpi Pills, comprising the following steps:

[0087] a) Preparation of single medicinal material sample solutions: prepare any one or more of the six medicinal material samples of Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Crataegus pinnatifida (fried), Fructus aurantii (fried), and Pericarpium Citri Reticulatae in Jianpi Pills according to step A) of the detection method of Jianpi Pills fingerprint, and obtain at least one single medicinal material sample solution respectively;

[0088] b) Preparation of negative sample solution: The six medicinal material samples of Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Hawthorn (fried), Immature Citrus aurantium (fried), and Tangerine peel were respectively lacking Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Hawthorn (fried), Immature Citrus aurantium (fried), and Tangerine peel, and were prepared according to step A) of the detection method of Jianpi Pill fingerprint, to obtain negative sample solutions lacking Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Hawthorn (fried), Immature Citrus aurantium (fried), and Tangerine peel;

[0089] c) Determination: using high performance liquid chromatography (HPLC) under the same chromatographic conditions as in step C) of the method for detecting the fingerprint of Jianpi Pills to respectively determine the fingerprints of the single medicinal material sample solution in step a) and the negative sample solution in step b);

[0090] d) Obtaining the control fingerprint: using the test solution prepared in step A) of the detection method for the fingerprint of Jianpi Pills, adopt the same step C) as the detection method for the fingerprint of Jianpi Pills to obtain the control fingerprint of Jianpi Pills;

[0091] e) Quality inspection: Compare the fingerprints of the single medicinal sample solution and the negative sample solution with the control fingerprint of Jianpi Pills. By the relative retention time, identify the corresponding characteristic peaks of the single medicinal sample solution in the control fingerprint of Jianpi Pills, so as to attribute and locate the characteristic peaks in the fingerprint of the single medicinal sample solution.

[0092] Preferably, in step a), the Codonopsis pilosula is the dried root of Codonopsis pilosula (Franch.) Nannf., a plant of the Campanulaceae family. The Atractylodes macrocephala (fried) is obtained by frying the dried rhizomes of Atractylodes macrocephala Koidz., a plant of the Asteraceae family. The malt (fried) is a fried processed product of the mature fruit of Hordeum vulgare L., a plant of the Gramineae family, which is germinated and dried. The hawthorn (fried) is obtained by frying the dried mature fruit of Crataegus pin,natiida Bge.var.majorN.E.Br. or Crataegus pin.nati fida Bge., a plant of the Rosaceae family. The Citrus aurantium (fried) is the dried young fruit of Citrus aurantium L., a plant of the Rutaceae family, and its cultivars or Citrussinensis Osbeck. The tangerine peel is the dried mature peel of the rutaceae plant Citrus reticulata Blanco and its cultivars.

[0093] Preferably, in step e), the present invention locates the characteristic peaks of the measured fingerprint of the single medicinal material sample solution and the control fingerprint of Jianpi Pills, uses the 2012 version of the software "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" issued by the State Pharmacopoeia Committee for analysis and processing, and confirms the attribution of the characteristic peaks of each single medicinal material of Jianpi Pills by the relative retention time of each characteristic peak on the control fingerprint of Jianpi Pills. Specific results are shown in Figure 2 , 7 and Table 4.

[0094] Table 4 Attribution of characteristic peaks of each single medicinal material of Jianpi Pills

[0095]

[0096] Preferably, in step e), in the single medicinal material sample solution, the fingerprint spectrum of the Codonopsis pilosula sample solution includes 1 common fingerprint peak, and the 1 common fingerprint peak is Peak 9.

[0097] Preferably, in step e), among the single medicinal material sample solutions, the fingerprint spectrum of the Atractylodes macrocephala (fried) sample solution includes 6 common fingerprint peaks, and the 6 common fingerprint peaks are Peak 1, Peak 2, Peak 22, Peak 23, Peak 24, Peak 25, Peak 14, and Peak 15.

[0098] Preferably, in step e), among the single medicinal material sample solutions, the fingerprint spectrum of the malt (fried) sample solution has no common fingerprint peak.

[0099] Preferably, in step e), among the single medicinal material sample solutions, the fingerprint spectrum of the Hawthorn (fried) sample solution includes two common fingerprint peaks, and the two common fingerprint peaks are Peak 1 and Peak 20.

[0100] Preferably, in step e), in the single medicinal material sample solution, the fingerprint spectrum of the Fructus Aurantii Immaturus (fried) sample solution includes 19 common fingerprint peaks, and the 19 common fingerprint peaks are Peak 1, Peak 3, Peak 4, Peak 5, Peak 6, Peak 7, Peak 8, Peak 9, Peak 10, Peak 12, Peak 13, Peak 14, Peak 15, Peak 16, Peak 17, Peak 18, Peak 19, and Peak 20.

[0101] Preferably, in step e), in the single medicinal material sample solution, the fingerprint spectrum of the tangerine peel sample solution includes 11 common fingerprint peaks, and the 11 common fingerprint peaks are peak 5, peak 6, peak 7, peak 9, peak 10, peak 11, peak 12, peak 14, peak 15, peak 20, and peak 21.

[0102] The water used in the present invention is all purified water.

[0103] As described above, the present invention provides a method for determining the fingerprint of Jianpi Pills and the content of multiple components. The fingerprint of Jianpi Pills is studied by HPLC, and the contents of 5 components (hesperidin, ferulic acid, naringin, neohesperidin, and Atractylodes lactone I) in the preparation are determined. The method establishes the fingerprint of Jianpi Pills, with a total of 25 common fingerprint peaks, and the total area of ​​the common peaks is more than 90% of the total area, and 8 index components are confirmed, and the characteristic peaks of the other 5 medicinal materials except malt among the 6 medicinal materials are well characterized in the fingerprint, and the attribution is confirmed. It shows that the fingerprint method is representative.

[0104] This method can compare the similarity of fingerprints of 20 batches of Jianpi Pills samples. Since there is no increase or loss in the number of peaks, the similarity of the fingerprints is high (all ≥ 0.99), and the overall quality of the batch samples is stable.

[0105] This method is fast and simple, and can systematically, quickly, truly and comprehensively evaluate the quality of drugs, and has good reproducibility and stability. This method aims to comprehensively analyze and evaluate the quality of Jianpi Pills, improve the scientific basis for controlling the quality of the drug, and thus ensure the safety of Jianpi Pills. BRIEF DESCRIPTION OF THE DRAWINGS

[0106] Figure 1 Shown is a comparison chromatogram of the Jianpi Pills sample and the mixed reference substance of the present invention, wherein S1 is the Jianpi Pills sample, S2 is the Jianpi Pills mixed reference substance, peak 1 is ferulic acid, peak 2 is naringin, peak 3 is neohesperidin, and peak 4 is Atractylodes lactone I.

[0107] Figure 2 Shown is the HPLC-DAD comparison chart of the Jianpi Pill sample of the present invention and the missing prescription.

[0108] Figure 3 Shown is a comparison chromatogram of the hesperidin reference substance of the present invention and the Jianpi Pills sample.

[0109] Figure 4 It shows the control fingerprint of the Jianpi Pill sample in the present invention, wherein peak 9 is ferulic acid, peak 10 is naringin, peak 11 is naringin, peak 12 is hesperidin, peak 13 is neohesperidin, peak 15 is galangin, peak 20 is nobiletin, and peak 25 is atractylodes lactone I.

[0110] Figure 5 It shows the HPLC superimposed fingerprints of 20 batches of Jianpi Pills samples and reference substances in the present invention, wherein S1 to S20 are 20 batches of Jianpi Pills samples; and R is the reference substance.

[0111] Figure 6 It shows a comparison diagram of the chromatogram of the reference substance in the present invention and the fingerprint of Jianpi Pills, wherein A is the chromatogram of the reference substance, B is the fingerprint of Jianpi Pills, peak 9 is ferulic acid, peak 10 is naringin, peak 11 is naringin, peak 12 is hesperidin, peak 13 is neohesperidin, peak 15 is galangin, peak 20 is nobiletin, and peak 25 is atractylodes lactone I.

[0112] Figure 7 It shows the attribution diagram of the characteristic peaks of the fingerprint spectrum of each single medicinal material in the Jianpi Pill sample of the present invention, wherein peak 9 is ferulic acid, peak 10 is naringin, peak 11 is naringin, peak 12 is hesperidin, peak 13 is neohesperidin, peak 15 is galangin, peak 20 is nobiletin, and peak 25 is atractylodes lactone I.

[0113] Figure 8 Shown is the HR-ESI-MA spectrum of galangin in the fingerprint spectrum of Jianpi Pills of the present invention.

[0114] Fig. 9 Shown is the HR-ESI-MA spectrum of nobiletin in the fingerprint spectrum of Jianpi Pills of the present invention. DETAILED DESCRIPTION

[0115] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention.

[0116] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0117] The reagents and instruments used in the following examples are as follows:

[0118] 1. Reagents

[0119] Reference substances: neohesperidin (batch number: 111857-201804, purity 99.4%, China Food and Drug Inspection Institute), naringin (batch number: 110722-201815, purity 91.7%, China Food and Drug Inspection Institute), atractylodes lactone I (batch number: 73069-13-3, purity ≥98%, Shanghai Standard Standard Technology Service Co., Ltd.), ferulic acid (batch number: 110773-200611, purity ≥98%, China Pharmaceutical Biological Products Co., Ltd. Testing Institute), hesperidin (Batch No.: 110721-202220, purity 97.2%, China Food and Drug Inspection Institute), naringin (Batch No.: 23081421, purity 98.00%, Shanghai Tongtian Biotechnology Co., Ltd.), cyperidin (Batch No.: 14259, purity ≥98.00%, Shanghai Shidande Standard Technical Services Co., Ltd.), nobiletin (Batch No.: 6082, purity 98.70%, Shanghai Shidande Standard Technical Services Co., Ltd.).

[0120] Samples: 20 batches of Jianpi Pills. See Table 5 for detailed information.

[0121] Table 5

[0122] Serial number batch number Serial number batch number 1 20230502-1 11 20230502-11 2 20230502-2 12 20230502-12 3 20230502-3 13 20230502-13 4 20230502-4 14 20230502-14 5 20230502-5 15 20230502-15 6 20230502-6 16 20230502-16 7 20230502-7 17 20230502-17 8 20230502-8 18 20230502-18 9 20230502-9 19 20230502-19 10 20230502-10 20 20230502-20

[0123] Negative samples: negative for lack of Codonopsis pilosula, negative for lack of Atractylodes macrocephala (fried), negative for lack of malt (fried), negative for lack of Crataegus pinnatifida (fried), negative for lack of Immature Citrus aurantium (fried) and negative for lack of Tangerine peel and each single medicinal material: Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), Crataegus pinnatifida (fried), Immature Citrus aurantium (fried), Tangerine peel were all provided by the Technical Center of Shanghai Hutchison Pharmaceuticals Co., Ltd.

[0124] Reagents: methanol (analytical grade AR, Sinopharm Chemical Reagent Co., Ltd.), acetonitrile (chromatographic grade, TEDIA, USA), formic acid (chromatographic grade, TEDIA, USA), and ultrapure water were prepared by a Milli-Q ultrapure water treatment system.

[0125] 2. Instruments

[0126] Agilent 1260 high performance liquid chromatograph (OpenLAB CDS2.1 chromatography workstation, G1312B binary pump, G1322A automatic degasser, G7116A column oven, G7115A DAD detector, G7129A autosampler, Agilent, USA); SB-5200DTD ultrasonic cleaner (Ningbo Xinzhi Biotechnology Co., Ltd.); AL204 and XS205 analytical electronic balances (METTLER TOLEDO Instrument Shanghai Co., Ltd.); Milli-Q Advantage A10 ultrapure water system (Merck Millipore, Germany).

[0127] Example 1

[0128] 1. Sample pretreatment

[0129] Preparation of test solution: Take the powder sample of Jianpi Pills batch 20230502-1, accurately weigh 1.0 g, put it in a 50 mL stoppered conical flask, accurately add 25 mL of methanol, stopper, weigh, and perform ultrasonic extraction (power 250 W, frequency 40 kHz) for 60 minutes. Let it stand and cool to room temperature, filter through a 0.45 μm microporous filter membrane, and take the filtrate to obtain the test solution 1#.

[0130] Preparation of reference solution: Precisely weigh ferulic acid, naringin, neohesperidin, and atractylodes lactone I reference substances, accurately weigh, place in the same 10 mL volumetric flask, dissolve with methanol and dilute to volume, shake well, and then dilute separately to prepare a series of first reference solution with different concentrations. In a series of first reference solutions with different concentrations, the content of ferulic acid ranges from 1.50 to 96.06 μg / mL, the content of naringin ranges from 1.87 to 119.99 μg / mL, the content of neohesperidin ranges from 1.88 to 120.11 μg / mL, and the content of atractylodes lactone I ranges from 0.75 to 48.11 μg / mL.

[0131] 2. Chromatographic conditions

[0132] The chromatographic conditions of the HPLC method are as follows: the chromatographic column is Agilent ZORBAX SB-C 18 Chromatographic column: chromatographic column (250 mm × 4.6 mm, 5 μm); detector: photodiode array detector (DAD); column temperature: 30 °C; injection volume: 10 μL; flow rate: 1 mL / min.

[0133] The analysis was performed using a multi-wavelength method, with detection wavelengths of 275nm, 300nm and 320nm. The specific situation is shown in Table 1, which is: 0-12min, detection wavelength is 275nm; 12-21min, detection wavelength is 300nm; 21-34min, detection wavelength is 275nm; 34-35min, detection wavelength is 320nm; 35-37min, detection wavelength is 275nm; 37-48min, detection wavelength is 300nm; 48-60min, detection wavelength is 275nm.

[0134] The mobile phase is acetonitrile-0.1% formic acid aqueous solution, wherein phase A is acetonitrile and phase B is 0.1% formic acid aqueous solution; the analysis time is 60 min; and the elution is gradient.

[0135] As shown in Table 1, the specific procedure of the gradient elution is:

[0136] 0-6min, the volume ratio of phase A:phase B was 5:95-22:78;

[0137] 6-17min, the volume ratio of phase A:phase B is 22:78-22:78;

[0138] 17-19 min, the volume ratio of phase A:phase B was 22:78-31:69;

[0139] 19-32min, the volume ratio of phase A:phase B was 31:69-43:57;

[0140] 32-36min, the volume ratio of phase A:phase B was 43:57-49:51;

[0141] 36-42min, the volume ratio of phase A:phase B was 49:51-63:37;

[0142] 42-44min, the volume ratio of phase A:phase B was 63:37-63:37;

[0143] 44-55min, the volume ratio of phase A:phase B was 63:37-95:5;

[0144] 55-60min, the volume ratio of phase A:phase B is 95:5-5:95.

[0145] 3. Determination

[0146] Using the external standard method, a series of different volumes of the first reference solution were pipetted to prepare a series of solutions with different concentrations, and the samples were analyzed by high performance liquid chromatography to draw a standard working curve. The obtained test solution was then analyzed by high performance liquid chromatography, and the analysis results were substituted into the standard working curve to obtain the contents of the four components in the test solution.

[0147] Specifically, a series of different volumes of the first reference solution are respectively transferred to prepare a series of solutions of different concentrations, and the samples are analyzed by high performance liquid chromatography to obtain the linear relationship between the content and peak area of ​​the four components in the first reference solution, and the corresponding standard working curve is drawn with the chromatographic peak area of ​​each component corresponding to its corresponding content, and the regression equation of each standard working curve is calculated. The test solution is then detected by high performance liquid chromatography, and the chromatographic peak areas of the four components in the test solution are respectively substituted into the regression equation of each standard working curve to obtain the content of the corresponding component.

[0148] Example 2

[0149] 1. Sample pretreatment

[0150] Preparation of test solution: Take the powder sample of Jianpi Pills batch 20230502-1, accurately weigh 50 mg, put it in a 50 mL stoppered conical flask, accurately add 25 mL of methanol, stopper, weigh, and extract by ultrasonic (power 250 W, frequency 40 kHz) for 60 minutes. Let it stand and cool to room temperature, filter through a 0.45 μm microporous filter membrane, and take the filtrate to obtain the test solution 2#.

[0151] Preparation of reference solution: accurately weigh the hesperidin reference substance, accurately weigh it, place it in the same 10mL volumetric flask, dissolve it with methanol and dilute it to the mark, shake it well, and then dilute it separately to prepare a series of second reference solutions of different concentrations. In a series of second reference solutions of different concentrations, the content of hesperidin ranges from 6.20 to 397μg / mL.

[0152] 3. Chromatographic conditions

[0153] The chromatographic conditions of the HPLC method are as follows: the chromatographic column is Agilent ZORBAX SB-C 18 Chromatographic column: chromatographic column (250 mm × 4.6 mm, 5 μm); detector: photodiode array detector (DAD); column temperature: 30 °C; injection volume: 10 μL; flow rate: 1 mL / min.

[0154] The analysis was performed using a multi-wavelength method, with detection wavelengths of 275 nm and 300 nm. The specific situation is shown in Table 2, which is: 0-12 min, detection wavelength of 275 nm; 12-21 min, detection wavelength of 300 nm; 21-37 min, detection wavelength of 275 nm; 37-48 min, detection wavelength of 300 nm; 48-60 min, detection wavelength of 275 nm.

[0155] The mobile phase is acetonitrile-0.1% formic acid aqueous solution, wherein phase A is acetonitrile and phase B is 0.1% formic acid aqueous solution; the analysis time is 60 min; and the elution is gradient.

[0156] As shown in Table 1, the specific procedure of the gradient elution is:

[0157] 0-6min, the volume ratio of phase A:phase B was 5:95-22:78;

[0158] 6-17min, the volume ratio of phase A:phase B is 22:78-22:78;

[0159] 17-19 min, the volume ratio of phase A:phase B was 22:78-31:69;

[0160] 19-32min, the volume ratio of phase A:phase B was 31:69-43:57;

[0161] 32-36min, the volume ratio of phase A:phase B was 43:57-49:51;

[0162] 36-42min, the volume ratio of phase A:phase B was 49:51-63:37;

[0163] 42-44min, the volume ratio of phase A:phase B was 63:37-63:37;

[0164] 44-55min, the volume ratio of phase A:phase B was 63:37-95:5;

[0165] 55-60min, the volume ratio of phase A:phase B is 95:5-5:95.

[0166] 3. Determination

[0167] Using the external standard method, a series of different volumes of the second reference solution were pipetted to prepare a series of solutions with different concentrations, and the samples were analyzed by high performance liquid chromatography to draw a standard working curve. The obtained test solution was then analyzed by high performance liquid chromatography, and the analysis results were substituted into the standard working curve to obtain the content of hesperidin in the test solution.

[0168] Specifically, a series of different volumes of the second reference solution are respectively transferred to prepare a series of solutions with different concentrations, and the linear relationship between the hesperidin content and the peak area in the second reference solution is obtained by sample injection analysis using a high performance liquid chromatograph, and the corresponding standard working curve is drawn with the chromatographic peak area of ​​hesperidin corresponding to its corresponding content, and the regression equation of the standard working curve is calculated. The test solution is then detected using a high performance liquid chromatograph, and the chromatographic peak area of ​​hesperidin in the test solution is respectively substituted into the regression equation of the standard working curve to obtain the content of hesperidin.

[0169] Example 3

[0170] 1. Sample pretreatment

[0171] Preparation of test solution: Take the powder sample of Jianpi Pills batch 20230502-1, accurately weigh 1.0 g, put it in a 50 mL stoppered conical flask, accurately add 24 mL of methanol, stopper, weigh, and perform ultrasonic extraction (power 250 W, frequency 40 kHz) for 58 minutes. Let it stand and cool to room temperature, filter through a 0.45 μm microporous filter membrane, and take the filtrate to obtain the test solution 3#.

[0172] Preparation of reference solution: Precisely weigh ferulic acid, naringin, neohesperidin, and Atractylodes lactone I reference substances, accurately weigh, place in the same 10 mL volumetric flask, dissolve and dilute to volume with methanol, shake well, and dilute again to prepare a series of first reference solutions of different concentrations. The concentration range of a series of first reference solutions of different concentrations is the same as step 1 in Example 1.

[0173] 2. Chromatographic conditions

[0174] The chromatographic conditions of the HPLC method are as follows: the chromatographic column is Agilent ZORBAX SB-C 18 Chromatographic column: chromatographic column (250 mm × 4.6 mm, 5 μm); detector: photodiode array detector (DAD); column temperature: 31 °C; injection volume: 9 μL; flow rate: 1.1 mL / min.

[0175] The analysis was performed using a multi-wavelength approach, and the detection wavelength was selected the same as in step 2 of Example 1.

[0176] The mobile phase is acetonitrile-0.12% formic acid aqueous solution, wherein phase A is acetonitrile and phase B is 0.12% formic acid aqueous solution; the analysis time is 60 min; gradient elution.

[0177] The specific procedure of gradient elution is the same as step 2 in Example 1.

[0178] 3. Determination

[0179] The specific determination process is the same as step 3 in Example 1.

[0180] Example 4

[0181] 1. Sample pretreatment

[0182] Preparation of test solution: Take the powder sample of Jianpi Pills batch 20230502-1, accurately weigh 50 mg, put it in a 50 mL stoppered conical flask, accurately add 26 mL of methanol, stopper, weigh, and extract by ultrasonic (power 250 W, frequency 40 kHz) for 61 minutes. Let it stand and cool to room temperature, filter through a 0.45 μm microporous filter membrane, and take the filtrate to obtain the test solution 4#.

[0183] Preparation of reference solution: accurately weigh the hesperidin reference substance, accurately weigh it, place it in the same 10 mL volumetric flask, dissolve it with methanol and dilute it to the mark, shake it well, and then dilute it separately to prepare a series of second reference solutions of different concentrations. The concentration range of a series of second reference solutions of different concentrations is the same as step 1 in Example 2.

[0184] 2. Chromatographic conditions

[0185] The chromatographic conditions of the HPLC method are as follows: the chromatographic column is Agilent ZORBAX SB-C 18 Chromatographic column: chromatographic column (250 mm × 4.6 mm, 5 μm); detector: photodiode array detector (DAD); column temperature: 29 °C; injection volume: 11 μL; flow rate: 0.9 mL / min.

[0186] The analysis was performed using a multi-wavelength approach, and the detection wavelength selection was the same as step 2 in Example 2.

[0187] The mobile phase is acetonitrile-0.09% formic acid aqueous solution, wherein phase A is acetonitrile and phase B is 0.09% formic acid aqueous solution; the analysis time is 60 min; gradient elution.

[0188] The specific procedure of gradient elution is the same as step 2 in Example 2.

[0189] 3. Determination

[0190] The specific determination process is the same as step 3 in Example 2.

[0191] Example 5

[0192] Accurately weigh appropriate amounts of ferulic acid, naringin, neohesperidin, and atractylodes lactone I, place them in the same 10 mL volumetric flask, dissolve them with methanol and dilute to the scale, shake well, and prepare a mixed reference solution with 96.06 μg of ferulic acid, 119.99 μg of naringin, 120.11 μg of neohesperidin, and 48.11 μg of atractylodes lactone I per 1 mL.

[0193] Accurately pipette 0.156mL, 0.312mL, 0.625mL, 1.25mL, 2.5mL, and 5mL of the mixed reference solution to 10mL. Inject 10μL of the sample according to the chromatographic conditions in step 2 of Example 1 for determination. With the peak area (Y) as the ordinate and the concentration (X) as the abscissa, draw a standard curve and perform regression calculation. The regression equation is shown in Table 6. The results show that the correlation coefficient R 2 Not less than 0.9991, and the linear relationship between the components is good.

[0194] Table 6

[0195]

[0196] The mixed reference solution was diluted to samples of different concentrations and analyzed, with a signal-to-noise ratio of 3:1 as the limit of detection (LOD) and a signal-to-noise ratio of 10:1 as the limit of quantification (LOQ). The results are shown in Table 7.

[0197] Table 7

[0198]

[0199] Example 6

[0200] 1. Method specificity

[0201] Take about 1.0 g of each of the six raw medicinal material powders, including Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), Immature Citrus aurantium (fried), and dried tangerine peel, and place them in a 50-mL stoppered conical flask. Accurately add 25 mL of methanol, stopper the flask, weigh the flask, and perform ultrasonic extraction (power 250 W, frequency 40 kHz) for 60 min. Cool the flask, filter it through a 0.45 μm filter membrane, and take the filtrate to obtain the sample solution of each single medicinal material.

[0202] The six medicinal material samples of Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), Citrus aurantium (fried), and dried tangerine peel were respectively lacking Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), Citrus aurantium (fried), and dried tangerine peel, and were prepared under the same conditions as above to obtain negative sample solutions lacking Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), Citrus aurantium (fried), and dried tangerine peel, respectively.

[0203] Take the first reference solution prepared in Example 1, the test solution and the negative sample solution prepared in Example 1 and perform the test according to step 2 of Example 1. The results are shown in Figure 1 At the same time, each negative sample solution was injected and tested according to step 2 of Example 1. The results are shown in Figure 2 .Depend on Figure 1 , 2 It can be seen that the method has good specificity.

[0204] 2. Precision

[0205] Take the Jianpi Pill sample with batch number 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 1, and perform the test according to step 2 in Example 1. Perform 6 injections for analysis and record the peak area. The results show that the RSD of the peak areas of ferulic acid, naringin, neohesperidin, and atractylodes lactone I are all less than 3.0%, indicating that the instrument has good precision.

[0206] 3. Stability

[0207] Take the Jianpi Pill sample with batch number 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 1, and perform the test according to step 2 in Example 1, inject samples at 0, 2, 4, 8, 12, 24, and 48 hours, and record the peak area. The results show that the RSD of the peak areas of ferulic acid, naringin, neohesperidin, and atractylodes lactone I are all less than 3.0%, indicating that the test solution has good stability within 48 hours.

[0208] 3. Repeatability

[0209] Take Jianpi Pills sample with batch number 20230502-1, prepare 6 test solutions according to step 1 in Example 1, accurately weigh 6 parts, perform detection according to step 2 in the above Example 1, and record the peak area. Results The RSD of the peak areas of ferulic acid, naringin, neohesperidin, and atractylodes lactone I were all less than 3.0%, indicating that the method had good repeatability.

[0210] 4. Sample recovery rate

[0211] Take 9 samples of Jianpi Pills with batch number 20230502-1, each about 0.5 g, accurately weighed, and added appropriate amounts of ferulic acid, naringin, neohesperidin, and Atractylodes lactone I reference substances at three different concentration levels, prepare the test solution according to step 1 in Example 1, detect according to step 2 in the above Example 1, record the chromatogram, and calculate the recovery rate of each component. The results are shown in Table 8, indicating that the method has good accuracy.

[0212] Table 8

[0213]

[0214]

[0215] Example 7

[0216] Take 20 batches of Jianpi Pills samples, prepare the test solution according to step 1 in Example 1, and analyze the samples according to the chromatographic conditions of step 2 in Example 1, record the chromatograms, and calculate the contents of ferulic acid, naringin, neohesperidin, and atractylodes lactone I in the 20 batches of Jianpi Pills. The results of the determination of the contents of the four components in the 20 batches of Jianpi Pills are shown in Table 8.

[0217] Table 8 Content determination results of 20 batches of Jianpi Pills (mg·g-1)

[0218]

[0219]

[0220] Example 8

[0221] Accurately weigh an appropriate amount of hesperidin, place it in a 10 mL volumetric flask, dissolve it with methanol and dilute it to the mark, shake well, and prepare a reference solution with 397 μg of hesperidin per 1 mL.

[0222] Accurately pipette 0.156mL, 0.312mL, 0.625mL, 1.25mL, 2.5mL, and 5mL of the mixed reference stock solution to 10mL. Inject 10μL of the sample under the chromatographic conditions of step 2 in Example 2 for determination. With the peak area (Y) as the ordinate and the concentration (X) as the abscissa, draw a standard curve and perform regression calculation. The results show that the components have a good linear relationship. The regression equation is shown in Table 9.

[0223] Table 9

[0224]

[0225] The above-mentioned reference solution was diluted to samples of different concentrations in turn for analysis, with a signal-to-noise ratio of 3:1 as the limit of detection (LOD) and a signal-to-noise ratio of 10:1 as the limit of quantification (LOQ). The results are shown in Table 10.

[0226] Table 10

[0227]

[0228] Example 9

[0229] 1. Precision

[0230] Take the Jianpi Pill sample with batch number 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 2, and perform the test according to step 2 in the above Example 2. Perform 6 injections for analysis and record the peak area. The results show that the RSD of the peak area of ​​hesperidin is less than 3.0%, indicating that the instrument has good precision.

[0231] 2. Stability

[0232] Take the Jianpi Pill sample with batch number 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 2, and perform the test according to step 2 in the above Example 2, inject the sample at 0, 2, 4, 8, 12, 24, and 48 hours, and record the peak area. The results show that the RSD of the hesperidin peak area is less than 3.0%, indicating that the test solution has good stability within 48 hours.

[0233] 3. Repeatability

[0234] Take Jianpi Pills sample with batch number 20230502-1, prepare 6 test solutions according to step 1 in Example 2, perform detection according to step 2 in the above Example 2, and record the peak area. The RSD of the peak area of ​​hesperidin was less than 3.0%, indicating that the method has good repeatability.

[0235] 4. Sample recovery rate

[0236] Nine samples of Jianpi Pills with batch number 20230502-1 were taken, each weighing about 0.25 mg, and accurately weighed. Appropriate amounts of hesperidin reference substance were added at three different concentration levels. The test solution was prepared according to step 1 in Example 2, and the test was performed according to step 2 in the above Example 2. The chromatogram was recorded, and the recovery rate of each component was calculated. The results are shown in Table 11, indicating that the accuracy of the method is good.

[0237] Table 11

[0238]

[0239] Example 10

[0240] Take 20 batches of Jianpi Pills samples, prepare the test solution according to step 1 in Example 2, and analyze the samples according to the chromatographic conditions of step 2 in Example 2, record the chromatograms, and calculate the content of hesperidin in the 20 batches of Jianpi Pills. The results of the determination of hesperidin content in 20 batches of Jianpi Pills are shown in Table 12. Figure 3 .

[0241] Table 12

[0242]

[0243]

[0244] Embodiment 11

[0245] 1. Sample pretreatment

[0246] Preparation of the test solution: The preparation process of the test solution is the same as that in step 1 of Example 1.

[0247] Preparation of reference solution: accurately weigh ferulic acid, naringin, neohesperidin, atractylodes lactone I, hesperidin, naringin, galangin, and nobiletin reference substances, dissolve them in methanol, make up to volume, and prepare the third reference solution.

[0248] 2. Chromatographic conditions

[0249] The chromatographic conditions of the HPLC are the same as those of the HPLC in step 2 of Example 1.

[0250] 3. Determination

[0251] The high performance liquid chromatography method with the chromatographic conditions in the above step 2 is used to measure the test solution and the third reference solution in the above step 1 respectively, and the fingerprint of the test solution and the fingerprint of the third reference solution are obtained. The fingerprint of the test solution is compared with the fingerprint of the third reference solution, and the corresponding characteristic peaks in the fingerprint of the test solution are identified by relative retention time according to the known characteristic peaks in the fingerprint of the third reference solution, so as to attribute and locate the index components in the fingerprint of the test solution and obtain the fingerprint of Jianpi Pills.

[0252] Example 12

[0253] The detection method of Jianpi Pills fingerprint established in the above Example 11 was used to detect 20 batches of Jianpi Pills, and the fingerprint of the test solution and the fingerprint of the reference solution were obtained. The fingerprint data of the test sample were imported into the 2012 version of the software "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" issued by the State Pharmacopoeia Committee, and the multi-point correction matching fingerprint time window was 0.2min. The fingerprint and the reference fingerprint were generated by the average method. The fingerprint of the test sample was compared with the reference fingerprint of Jianpi Pills obtained under the same fingerprint detection conditions for similarity, and the similarity of each batch of Jianpi Pills fingerprint was calculated. 25 common peaks were calibrated. The results of the comparison of the similarity between the fingerprints of the 20 batches of test samples and the reference fingerprints showed that the similarities of S1 to S20 were all greater than 0.99, as shown in Table 13, indicating that the overall quality of each batch of samples was relatively stable. The reference fingerprints of 20 batches of Jianpi Pills are shown in Table 13. Figure 4 , the fingerprint spectrum overlay and its common patterns are shown in Figure 5 .

[0254] Table 13

[0255]

[0256]

[0257] Example 13

[0258] The Jianpi Pills were tested using the fingerprint detection method of the Jianpi Pills established in Example 11. Based on the fingerprints of the test solution and the reference solution, 25 common fingerprint peaks were identified. Figure 6As shown, the proportion of the 25 common peaks in the total peak area is more than 90%. Among them, peak No. 12 has a moderate elution time, good separation, and a large peak area, so peak No. 12 is selected as the reference peak (S peak), and the relative retention time of the other peaks is calculated. Therefore, taking peak No. 12 as the reference peak (S peak, the relative retention time is 1.0000), the relative retention times of the other 24 peaks are peak No. 1 (0.2411), peak No. 2 (0.2884), peak No. 3 (0.4558), peak No. 4 (0.4957), peak No. 5 (0.6639), peak No. 6 (0.7026), peak No. 7 (0.7127), peak No. 8 (0.7514), peak No. 9 (0.7675), peak No. 10 (0.9265), peak No. 11 (0.9 722), Peak 13 (1.0442), Peak 14 (1.0847), Peak 15 (1.1980), Peak 16 (1.2170), Peak 17 (1.3964), Peak 18 (1.4168), Peak 19 (1.4664), Peak 20 (1.4851), Peak 21 (1.4997), Peak 22 (1.5250), Peak 23 (1.5353), Peak 24 (1.5422), Peak 25 (1.5973).

[0259] Through Figure 6 By comparison, it was determined that Peak 9 was the fingerprint peak of ferulic acid; Peak 10 was the fingerprint peak of naringin; Peak 11 was the fingerprint peak of naringin; Peak 12 was the fingerprint peak of hesperidin; Peak 13 was the fingerprint peak of neohesperidin; Peak 15 was the fingerprint peak of galangin; Peak 20 was the fingerprint peak of nobiletin; and Peak 25 was the fingerprint peak of atractylodes lactone I.

[0260] Among them, peaks 15 and 20 were identified by mass spectrometry. The specific test results are shown in Figure 8 , 9 HR-ESI-MS showed that the quasi-molecular ion peak of peak 15 was 595.2021 [m+H] + , the molecular formula was obtained by using Mass Hunter B.04 software: C 28 H 34 O 14 HR-ESI-MS m / z shows that the quasi-molecular ion peak of peak 20 is 403.1380 [m+H] + , the molecular formula was obtained by using MassHunter B.04 software: C 21 H 22O8. Corresponding data and literature: Zheng Yuying, Pang Wenjing, Bai Yang, et al. Systematic analysis of chemical components of traditional and broken-wall pieces of Citrus aurantium based on UFLC-Triple TOF-MS / MS technology [J]. Central South Pharmacy, 2018, 16(04): 443-450. The records are consistent, that is, peak 15 is determined to be fennel glycosides and peak 20 is nobiletin.

[0261] Embodiment 14

[0262] 1. Precision

[0263] Take the same batch of Jianpi Pills 20230502-1, prepare 1 test solution according to step 1 in Example 11, and detect according to step 2 in the above Example 11, inject 6 times continuously, record the chromatogram, take hesperidin as the reference peak, calculate the RSD of the relative retention time of each common peak <1.0%, and the RSD of the relative peak area <3.0%, indicating that the precision of the instrument is good.

[0264] 2. Repeatability

[0265] Take the same batch of Jianpi Pills 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 11, detect according to step 2 in the above Example 11, record the chromatogram, take hesperidin as the reference peak, calculate the RSD of the relative retention time of each common peak <1.0%, and the RSD of the relative peak area <3.0%. The results show that the method has good repeatability.

[0266] 3. Stability

[0267] Take the same batch of Jianpi Pills 20230502-1, prepare 1 portion of the test solution according to step 1 in Example 11, and detect according to step 2 in the above Example 11, inject samples at 0, 2, 4, 8, 12, and 24 h, record the chromatogram, take hesperidin as the reference peak, calculate the RSD of the relative retention time of each common peak <1.0%, and the RSD of the relative peak area <3.0%. The results show that the test solution has good stability within 24 h.

[0268] Embodiment 15

[0269] The test solution was prepared by using step 1 in Example 11 above.

[0270] Six medicinal material powders of Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Crataegus pinnatifida (fried), Fructus aurantii (fried), and Pericarpium Citri Reticulatae were taken respectively, and six single medicinal material sample solutions were prepared by using step 1 in the above Example 6.

[0271] The test solution and the six single herbal sample solutions were measured by step 2 in Example 11 to obtain the test solution and the six single herbal sample solutions. The attribution was confirmed by the retention time of the chromatographic peak of each single herbal sample solution and the chromatographic peak of the Jianpi Pill fingerprint. Figure 7 , Table 4.

[0272] Depend on Figure 7 As shown in Table 4, the characteristic peaks of 5 out of 6 medicinal materials are well represented in the fingerprint spectrum and their attribution is confirmed.

[0273] In summary, the present invention provides a Jianpi Pill fingerprint spectrum and a method for determining the content of multiple components, which can quantitatively analyze the five components in Jianpi Pill, and also establishes a high-performance liquid fingerprint spectrum of Jianpi Pill, providing eight index components of the six medicinal materials in Jianpi Pill, thereby improving the scientific basis for controlling the quality of the medicine. Therefore, the present invention overcomes various shortcomings in the prior art and has a high industrial utilization value.

[0274] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. A method for determining the contents of multiple components in Jianpi Pills, comprising the following steps: 1) Preparation of the test solution: dissolve the Jianpi Pill sample in a solvent, extract with ultrasound, cool, filter, and take the filtrate to obtain the test solution; 2) Preparation of the first reference solution and / or the second reference solution, comprising any one or more of the following steps: 21) Add the reference substances of ferulic acid, naringin, neohesperidin and atractylodes lactone I into the solvent, dissolve them and then make up to volume to obtain the first reference substance solution; 22) Add the solvent to the hesperidin reference substance, dissolve it and then make up the volume to obtain the second reference substance solution; 3) Determination: The test solution of step 1), the first reference solution of step 21) and / or the second reference solution of step 22) are respectively determined by high performance liquid chromatography, and the contents of the five components in the test solution are calculated by external standard method.

2. The method for determining the contents of various components in Jianpi Pills according to claim 1, characterized in that: In step 1), 2) or 3), any one or more of the following conditions are included: A1) in step 1), the Jianpi Pills sample is a powder sample obtained by crushing the Jianpi Pills; A2) In step 1) or 2), the solvent is methanol; A3) In step 1), the ratio of the weight of the Jianpi Pills sample added to the volume of the solvent added is 0.01-1.5:25, g / mL; preferably, the ratio of the weight of the Jianpi Pills sample added to the volume of the solvent added is 0.04-1.1:25, g / mL; A4) In step 1), the ultrasonic extraction time is 40-80 min; A5) In step 1), the power of the ultrasonic extraction is 200-300W; the frequency of the ultrasonic extraction is 30-50kHz; A6) In step 1), the filtration is membrane filtration; preferably, the membrane is a 0.45 μm membrane; A7) In step 21), the content of ferulic acid in the first reference solution is in the range of 1.50-96.06 μg / mL; the content of naringin is in the range of 1.87-119.99 μg / mL; the content of neohesperidin is in the range of 1.88-120.11 μg / mL; and the content of atractylodes lactone I is in the range of 0.75-48.11 μg / mL; A8) In step 22), the content of hesperidin in the second reference solution is in the range of 6.20-397 μg / mL; A9) In step 3), the chromatographic column in the high performance liquid chromatography is C 18 Chromatographic column; preferably, the chromatographic column in the high performance liquid chromatography is Agilent ZORBAX SB-C 18 Chromatographic column, 250 mm × 4.6 mm, 5 μm; A10) In step 3), the detector in the high performance liquid chromatography is a photodiode array detector; A11) In step 3), the column temperature in the HPLC method is 25-35°C; A12) In step 3), the injection volume in the HPLC method is 5-20 μL; A13) In step 3), the flow rate in the high performance liquid chromatography is 0.5-2 mL / min; A14) In step 3), the detection wavelength in the high performance liquid chromatography is selected from one or more combinations of 274-276 nm, 299-301 nm, and 319-321 nm; preferably, the detection wavelength in the high performance liquid chromatography is selected from one or more combinations of 275 nm, 300 nm, and 320 nm; A15) In step 3), the mobile phase in the high performance liquid chromatography is acetonitrile-formic acid aqueous solution; A16) In step 3), the high performance liquid chromatography method uses gradient elution and the analysis time is 60 min.

3. The method for determining the contents of various components in Jianpi Pills according to claim 2, characterized in that: A3), when detecting four ingredients in Jianpi Pills: ferulic acid, naringin, neohesperidin, and Atractylodes lactone I, the ratio of the weight of the Jianpi Pills sample added to the volume of the solvent added is 0.9-1.1:25, g / mL; when detecting hesperidin in Jianpi Pills, the ratio of the weight of the Jianpi Pills sample added to the volume of the solvent added is 0.04-0.06:25, g / mL.

4. The method for determining the contents of various components in Jianpi Pills according to claim 2, characterized in that: In step 3), any one or more of the following conditions are also included: A141) When detecting four ingredients in Jianpi Pills: ferulic acid, naringin, neohesperidin, and Atractylodes lactone I, the detection wavelengths are 275 nm, 300 nm, and 320 nm; preferably, the detection wavelength changes with the time of the gradient elution program, and the specific changes are: 0-12 min, the detection wavelength is 275 nm; 12-21 min, the detection wavelength is 300 nm; 21-34 min, the detection wavelength is 275 nm; 34-35 min, the detection wavelength is 320 nm; 35-37 min, the detection wavelength is 275 nm; 37-48 min, the detection wavelength is 300 nm; 48-60 min, the detection wavelength is 275 nm; A142) When detecting hesperidin in Jianpi Pills, the detection wavelength is 275nm and 300nm; preferably, the detection wavelength changes with the time of the gradient elution program, and the specific change is: 0-12min, the detection wavelength is 275nm; 12-21min, detection wavelength is 300nm; 21-37min, detection wavelength is 275nm; 37-48min, detection wavelength is 300nm; 48-60min, detection wavelength is 275nm; A151) In the high performance liquid chromatography, the mobile phase is acetonitrile-0.08-0.12% formic acid aqueous solution; A161) The specific procedure of the gradient elution is: 0-6min, the volume ratio of phase A:phase B was 4-6:94-96-21-23:77-79; 6-17min, the volume ratio of phase A:phase B is 21-23:77-79-21-23:77-79; 17-19min, the volume ratio of phase A:phase B is 21-23:77-79-30-32:68-70; 19-32min, the volume ratio of phase A:phase B is 30-32:68-70-42-44:56-58; 32-36min, the volume ratio of phase A:phase B is 42-44:56-58-48-50:50-52; 36-42min, the volume ratio of phase A:phase B is 48-50:50-52-62-64:36-38; 42-44min, the volume ratio of phase A:phase B is 62-64:36-38-62-64:36-38; 44-55min, the volume ratio of phase A:phase B is 62-64:36-38-94-96:4-6; 55-60min, the volume ratio of phase A:phase B is 94-96:4-6-4-6:94-96.

5. A method for detecting the fingerprint of Jianpi Pills, comprising the following steps: A) Preparation of the test solution: the same as step 1) of the method for determining the contents of multiple components in Jianpi Pills according to any one of claims 1 to 4; B) Preparation of the third reference solution: adding a solvent to the reference substances of ferulic acid, naringin, neohesperidin, atractylodes lactone I, hesperidin, naringin, fennel glycosides, and nobiletin, dissolving them and then fixing the volume to prepare the third reference solution; C) Determination: adopt the high performance liquid chromatography under the same chromatographic conditions as step 3) of the method for determining the contents of multiple components in Jianpi Pills according to any one of claims 1 to 4, respectively determine the test solution of step A) and the third reference solution of step B), obtain the fingerprint of the test solution and the fingerprint of the third reference solution, compare the fingerprint of the test solution with the fingerprint of the third reference solution, attribute and locate the index components in the fingerprint of the test solution, thereby obtaining the fingerprint of Jianpi Pills.

6. Use of the detection method of Jianpi Pills fingerprint spectrum according to claim 5 in the quality detection of ingredients in Jianpi Pills.

7. A quality detection method for Jianpi Pills, comprising obtaining a Jianpi Pills fingerprint spectrum by using the Jianpi Pills fingerprint spectrum detection method described in claim 5, and comparing the obtained Jianpi Pills fingerprint spectrum with a control fingerprint spectrum of Jianpi Pills obtained under the same fingerprint spectrum detection conditions for similarity.

8. The quality detection method of Jianpi Pills according to claim 7, characterized in that: The control fingerprint of Jianpi Pills is obtained under the same conditions as the detection method of the Jianpi Pills fingerprint spectrum according to claim 5, and the control fingerprint of Jianpi Pills includes 25 common fingerprint peaks, with peak 12 as the reference peak S peak, the relative retention time is 1.0000, and the relative retention times of the other 24 peaks are peak 1 0.2411±0.0010, peak 2 0.2884±0.0008, peak 3 0.4558±0.0003, peak 4 0.4957±0.0005, peak 5 0.6639±0.0019, peak 6 0.7026±0.0015, peak 7 0.7127±0.0015, peak 8 0.7514±0.0011, peak 9 0.7675±0.0007, peak 10 0 .9265±0.0015, peak 11 0.9722±0.0005, peak 13 1.0442±0.0007, peak 14 1.0847±0.0015, peak 15 1.1980±0.0025, peak 16 1.2170±0.0019, peak 17 1.3964±0.0018, peak 18 1.4168± 0.0023, peak 19 1.4664±0.0023, peak 20 1.4851±0.0025, peak 21 1.4997±0.0026, peak 22 1.5250±0.0026, peak 23 1.5353±0.0006, peak 24 1.5422±0.0012, peak 25 1.5973±0.0015.

9. The quality detection method of Jianpi Pills according to claim 8, characterized in that: The control fingerprint of the Jianpi Pills was compared with the fingerprint of the third reference solution, and it was determined that the peak No. 9 was the fingerprint peak of ferulic acid; the peak No. 10 was the fingerprint peak of naringin; the peak No. 11 was the fingerprint peak of naringin; the peak No. 12 was the fingerprint peak of hesperidin; the peak No. 13 was the fingerprint peak of neohesperidin; the peak No. 15 was the fingerprint peak of fennel glycoside; and the peak No. 20 was the fingerprint peak of nobiletin; Peak 25 is the fingerprint peak of Atractylodes lactone I.

10. A method for screening fingerprints of multiple medicinal materials in Jianpi Pills, comprising the following steps: a) Preparation of single medicinal material sample solutions: prepare any one or more of the six medicinal material samples of Codonopsis pilosula, Atractylodes macrocephala (fried), Malt (fried), Crataegus pinnatifida (fried), Fructus aurantii (fried), and Pericarpium Citri Reticulatae in Jianpi Pills according to step A) of the Jianpi Pills fingerprint detection method of claim 5, and obtain at least one single medicinal material sample solution respectively; b) Preparation of negative sample solution: The six medicinal material samples of Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), immature bitter orange (fried), and dried tangerine peel lack Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), immature bitter orange (fried), and dried tangerine peel, respectively, and are prepared according to step A) of the detection method of Jianpi Pill fingerprint spectrum as described in claim 5, to obtain negative sample solutions lacking Codonopsis pilosula, Atractylodes macrocephala (fried), malt (fried), hawthorn (fried), immature bitter orange (fried), and dried tangerine peel; c) Determination: using high performance liquid chromatography under the same chromatographic conditions as in step C) of the method for detecting the fingerprint of Jianpi Pills according to claim 5 to respectively determine the fingerprint of the single medicinal material sample solution in step a) and the negative sample solution in step b); d) Obtaining the control fingerprint: using the test solution prepared in step A) of the method for detecting the fingerprint of Jianpi Pills according to claim 5, and adopting the same step C) as the method for detecting the fingerprint of Jianpi Pills according to claim 5 to obtain the control fingerprint of Jianpi Pills; e) Quality inspection: Compare the fingerprints of the single medicinal sample solution and the negative sample solution with the control fingerprint of Jianpi Pills. By the relative retention time, identify the corresponding characteristic peaks of the single medicinal sample solution in the control fingerprint of Jianpi Pills, so as to attribute and locate the characteristic peaks in the fingerprint of the single medicinal sample solution.

Citation Information

Patent Citations

  • Fingerprint spectrum of middle-jiao and qi tonifying pill and determination method of multi-component content of middle-jiao and qi tonifying pill

    CN116858966A

Cited By

  • Establishment method of spleen tonifying granule UPLC fingerprint spectrum, fingerprint spectrum and application thereof

    CN120971625A

  • Method for detecting multi-component content of Jianpi granules

    CN122793914A